Advertisement
U.S. markets closed

PURE Bioscience, Inc. (PURE)

Other OTC - Other OTC Delayed Price. Currency in USD
0.0880-0.0020 (-2.22%)
At close: 10:27AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0900
Open0.0900
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0880 - 0.0900
52 Week Range0.0700 - 0.1700
Volume8,635
Avg. Volume35,505
Market Cap9.843M
Beta (5Y Monthly)0.08
PE Ratio (TTM)N/A
EPS (TTM)-0.0400
Earnings DateJun 12, 2024 - Jun 17, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for PURE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • PURE BIOSCIENCE
    Daily – Vickers Top Insider Picks for 12/07/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    last yearArgus Research
View more
  • Business Wire

    PURE Bioscience Reports Fiscal Second Quarter 2024 Financial Results

    EL CAJON, Calif., March 18, 2024--PURE Bioscience, Inc. (OTCQB: PURE) ("PURE," the "Company" or "we"), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal second quarter ended January 31, 2024.

  • Business Wire

    PURE Bioscience Reports Fiscal First Quarter 2024 Financial Results

    EL CAJON, Calif., December 14, 2023--PURE Bioscience, Inc. (OTCQB: PURE) ("PURE," the "Company" or "we"), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal first quarter ended October 31, 2023.

  • Business Wire

    PURE Bioscience Reports Fiscal 2023 Financial Results

    EL CAJON, Calif., October 30, 2023--PURE Bioscience, Inc. (OTCQB: PURE) ("PURE," the "Company" or "we"), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal year ended July 31, 2023.